E6011 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Crohn's Disease
Conditions
Crohn's Disease
Trial Timeline
Apr 25, 2019 → Apr 3, 2024
NCT ID
NCT03733314About E6011 + Placebo
E6011 + Placebo is a phase 2 stage product being developed by Eisai for Crohn's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03733314. Target conditions include Crohn's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03733314 | Phase 2 | Completed |
| NCT03092765 | Phase 2 | Terminated |
| NCT02960490 | Phase 2 | Completed |
| NCT02960438 | Phase 2 | Completed |
| NCT02249078 | Phase 1 | Withdrawn |
| NCT02146261 | Phase 1 | Completed |
Competing Products
20 competing products in Crohn's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CT-P13 + Remicade | Celltrion | Phase 3 | 77 |
| CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 | Celltrion | Phase 1 | 33 |
| CT-P13 SC (Infliximab) | Celltrion | Phase 3 | 77 |
| CP-461 | Astellas Pharma | Phase 2 | 52 |
| E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kg | Eisai | Phase 1/2 | 41 |
| E6011 + Placebo | Eisai | Phase 1 | 33 |
| adalimumab + adalimumab + placebo | Eisai | Phase 2/3 | 65 |
| adalimumab | Eisai | Phase 2/3 | 65 |
| Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + Placebo | Eli Lilly | Phase 3 | 77 |
| Mirikizumab | Eli Lilly | Phase 3 | 77 |
| Mirikizumab + Mirikizumab + Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| Mirikizumab + Placebo | Eli Lilly | Phase 2 | 52 |
| Mirikizumab | Eli Lilly | Phase 3 | 77 |
| Matching Placebo for Upadacitinib + Upadacitinib | AbbVie | Phase 3 | 77 |
| Adalimumab + Placebo | AbbVie | Phase 3 | 77 |
| Upadacitinib + Placebo for Upadacitinib | AbbVie | Phase 3 | 77 |
| Placebo + ABT-494 | AbbVie | Phase 2 | 52 |
| ABT-494 | AbbVie | Phase 2 | 52 |
| Risankizumab + Comparator | AbbVie | Pre-clinical | 23 |
| placebo for risankizumab + risankizumab IV + risankizumab SC | AbbVie | Phase 3 | 77 |